Skip to main content

Advertisement

SpringerLink
Log in

Breast Cancer Resistance Protein (BCRP) and Sulfotransferases Contribute Significantly to the Disposition of Genistein in Mouse Intestine

  • Research Article
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

The low bioavailability of genistein has impeded its development into a therapeutic agent. Our earlier studies indicate that glucuronidation is one of the major barriers to genistein oral bioavailability. This study will determine how sulfotransferases and efflux transporters affect its intestinal disposition. A rodent intestinal perfusion model and S9 fractions were used. Sulfate excretion rates were comparable to glucuronide excretion in mouse small intestine but significantly higher than glucuronide excretion in mouse colon, which is different from rat intestinal disposition but similar to disposition in Caco-2 cells. To define efflux transporter(s) involved in sulfate excretion, two organic anion inhibitors (estrone sulfate and dihydroepiandrosterone sulfate) or a multidrug resistance protein inhibitor (MK-571) were used but neither was able to decrease the excretion of genistein sulfates. In contrast, the excretion of genistein sulfate decreased substantially (>90%) in small intestine of breast cancer resistance protein (BCRP) knockout mice and became undetectable in colon of the knockout mice. The excretion rates of genistein glucuronide in the small intestine of BCRP knockout mice were also significant decreased (78%). This study shows clearly that BCRP facilitates the cellular genistein sulfate excretion by removing sulfates to prevent their backward hydrolysis and to limit substrate inhibition, indicating that BCRP plays a dominant role in genistein sulfate excretion and a significant role in genistein glucuronide excretion in the mouse intestine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

REFERENCES

  1. Kurzerand MS, Xu X. Dietary phytoestrogens. Annu Rev Nutr. 1997;17:353–81.

    Article  Google Scholar 

  2. Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R, Elgavish A. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr. 2002;132:552S–8S.

    PubMed  Google Scholar 

  3. Cao F, Jin TY, Zhou YF. Inhibitory effect of isoflavones on prostate cancer cells and PTEN gene. Biomed Environ Sci. 2006;19:35–41.

    PubMed  CAS  Google Scholar 

  4. Gu Y, Zhu CF, Iwamoto H, Chen JS. Genistein inhibits invasive potential of human hepatocellular carcinoma by altering cell cycle, apoptosis, and angiogenesis. World J Gastroenterol. 2005;11:6512–17.

    PubMed  CAS  Google Scholar 

  5. Kim EJ, Shin HK, Park JH. Genistein inhibits insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: a possible mechanism of the growth inhibitory effect of Genistein. J Med Food. 2005;8:431–8.

    Article  PubMed  CAS  Google Scholar 

  6. Setchell KD, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr. 2001;131:1362S–75S.

    PubMed  CAS  Google Scholar 

  7. Busby MG, Jeffcoat AR, Bloedon LT, Koch MA, Black T, Dix KJ, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr. 2002;75:126–36.

    PubMed  CAS  Google Scholar 

  8. Gopalakrishnan A, Xu CJ, Nair SS, Chen C, Hebbar V, Kong AN. Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells. Arch Pharm Res. 2006;29:633–44.

    Article  PubMed  CAS  Google Scholar 

  9. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA. 1993;90:2690–4.

    Article  PubMed  CAS  Google Scholar 

  10. Vermaand SP, Goldin BR. Effect of soy-derived isoflavonoids on the induced growth of MCF-7 cells by estrogenic environmental chemicals. Nutr Cancer. 1998;30:232–9.

    Article  Google Scholar 

  11. Liuand Y, Hu M. Absorption and metabolism of flavonoids in the caco-2 cell culture model and a perused rat intestinal model. Drug Metab Dispos. 2002;30:370–7.

    Article  Google Scholar 

  12. King RA, Broadbent JL, Head RJ. Absorption and excretion of the soy isoflavone genistein in rats. J Nutr. 1996;126:176–82.

    PubMed  CAS  Google Scholar 

  13. Rimbach G, Weinberg PD, de Pascual-Teresa S, Alonso MG, Ewins BA, Turner R, et al. Sulfation of genistein alters its antioxidant properties and its effect on platelet aggregation and monocyte and endothelial function. Biochim Biophys Acta. 2004;1670:229–37.

    PubMed  CAS  Google Scholar 

  14. Barnes S, Sfakianos J, Coward L, Kirk M. Soy isoflavonoids and cancer prevention. Underlying biochemical and pharmacological issues. Adv Exp Med Biol. 1996;401:87–100.

    PubMed  CAS  Google Scholar 

  15. Allred CD, Twaddle NC, Allred KF, Goeppinger TS, Churchwell MI, Ju YH, et al. Soy processing affects metabolism and disposition of dietary isoflavones in ovariectomized BALB/c mice. J Agric Food Chem. 2005;53:8542–50.

    Article  PubMed  CAS  Google Scholar 

  16. Chen J, Lin H, Hu M. Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J Pharmacol Exp Ther. 2003;304:1228–35.

    Article  PubMed  CAS  Google Scholar 

  17. Chen J, Lin H, Hu M. Absorption and metabolism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model. Cancer Chemother Pharmacol. 2005;55:159–69.

    Article  PubMed  CAS  Google Scholar 

  18. Hu M, Chen J, Lin H. Metabolism of flavonoids via enteric recycling: mechanistic studies of disposition of apigenin in the Caco-2 cell culture model. J Pharmacol Exp Ther. 2003;307:314–21.

    Article  PubMed  CAS  Google Scholar 

  19. Jia X, Chen J, Lin H, Hu M. Disposition of flavonoids via enteric recycling: enzyme-transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates. J Pharmacol Exp Ther. 2004;310:1103–13.

    Article  PubMed  CAS  Google Scholar 

  20. Chen J, Wang S, Jia X, Bajimaya S, Tam V, Hu M. Disposition of flavonoids via recycling: comparison of intestinal versus hepatic disposition. Drug Metab Dispos. 2005;33:1777–84.

    PubMed  CAS  Google Scholar 

  21. Jeong EJ, Jia X, Hu M. Disposition of formononetin via enteric recycling: metabolism and excretion in mouse intestinal perfusion and Caco-2 cell models. Mol Pharm. 2005;2:319–28.

    Article  PubMed  CAS  Google Scholar 

  22. Wang SW, Chen J, Jia X, Tam VH, Hu M. Disposition of flavonoids via enteric recycling: structural effects and lack of correlations between in vitro and in situ metabolic properties. Drug Metab Dispos. 2006;34:1837–48.

    Article  PubMed  CAS  Google Scholar 

  23. Hu M, Sinko PJ, de Meere AL, Johnson DA, Amidon GL. Membrane permeability parameters for some amino acids and beta-lactam antibiotics: application of the boundary layer approach. J Theor Biol. 1988;131:107–14.

    Article  PubMed  CAS  Google Scholar 

  24. Hu M, Roland K, Ge L, Chen J, Li Y, Tyle P, et al. Determination of absorption characteristics of AG337, a novel thymidylate synthase inhibitor, using a perfused rat intestinal model. J Pharm Sci. 1998;87:886–90.

    Article  PubMed  CAS  Google Scholar 

  25. Jeong EJ, Lin H, Hu M. Disposition mechanisms of raloxifene in the human intestinal Caco-2 model. J Pharmacol Exp Ther. 2004;310:376–85.

    Article  PubMed  CAS  Google Scholar 

  26. Adachi Y, Suzuki H, Schinkel AH, Sugiyama Y. Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. Mol Pharmacol. 2005;67:923–8.

    Article  PubMed  CAS  Google Scholar 

  27. Ebert B, Seidel A, Lampen A. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis. 2005;26:1754–63.

    Article  PubMed  CAS  Google Scholar 

  28. Zhang S, Wang X, Sagawa K, Morris ME. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Drug Metab Dispos. 2005;33:341–8.

    Article  PubMed  CAS  Google Scholar 

  29. Bobrowska-Hagerstrand M, Wrobel A, Rychlik B, Ohman I, Hagerstrand H. Flow cytometric monitoring of multidrug drug resistance protein 1 (MRP1/ABCC1) -mediated transport of 2′, 7′-bis-(3-carboxypropyl)-5-(and-6)- carboxyfluorescein (BCPCF) into human erythrocyte membrane inside-out vesicles. Mol Membr Biol. 2007;24:485–95.

    Article  PubMed  CAS  Google Scholar 

  30. Zhang L, Lin G, Kovacs B, Jani M, Krajcsi P, Zuo Z. Mechanistic study on the intestinal absorption and disposition of baicalein. Eur J Pharm Sci. 2007;31:221–31.

    Article  PubMed  CAS  Google Scholar 

  31. Abbott BL. ABCG2 (BCRP): a cytoprotectant in normal and malignant stem cells. Clin Adv Hematol Oncol. 2006;4:63–72.

    PubMed  Google Scholar 

  32. Vander Borght S, Libbrecht L, Katoonizadeh A, van Pelt J, Cassiman D, Nevens F, et al. Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences. J Histochem Cytochem. 2006;54:1051–9.

    Article  PubMed  CAS  Google Scholar 

  33. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21:2895–900.

    PubMed  CAS  Google Scholar 

  34. Shelnutt SR, Cimino CO, Wiggins PA, Ronis MJ, Badger TM. Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. Am J Clin Nutr. 2002;76(3):588–94.

    PubMed  CAS  Google Scholar 

  35. Gu L, House SE, Prior RL, Fang N, Ronis MJ, Clarkson TB, et al. Metabolic phenotype of isoflavones differ among female rats, pigs, monkeys, and women. J Nutr. 2006;136(5):1215–21.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacological and Pharmaceutical Sciences, University of Houston, 1441 Moursund Street, Houston, Texas, 77030, USA

    Wei Zhu, Haiyan Xu, Stephen W. J. Wang & Ming Hu

Authors
  1. Wei Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haiyan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen W. J. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ming Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ming Hu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhu, W., Xu, H., Wang, S.W.J. et al. Breast Cancer Resistance Protein (BCRP) and Sulfotransferases Contribute Significantly to the Disposition of Genistein in Mouse Intestine. AAPS J 12, 525–536 (2010). https://doi.org/10.1208/s12248-010-9209-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12248-010-9209-x

Key words

Search

Navigation